Efficacy and Safety of Healsea® Babykids in the Treatment of Acute Infectious Rhinitis Symptoms in Children
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Lallemand Pharma AG
- Enrollment
- 200
- Locations
- 3
- Primary Endpoint
- The Area Under the Curve (AUC) of the Global Score of the Acute Rhinitis Symptoms Severity Questionnaire (ARSSQ) During First 10 Days of Symptoms - Full Analysis Set (FAS)
Study Overview
Brief Summary
The purpose of this post market clinical investigation is to demonstrate that Healsea® Babykids alleviates symptoms of the acute rhinitis phase with better efficacy than isotonic saline solution used as Placebo in children above 2 years.
Detailed Description
Healsea® Babykids is an isotonic saline solution based nasal spray supplemented with a natural Symbiofilm® extract (0.04%) isolated from marine bacteria. Symbiofilm® has in vitro antibiofilm activity and protects in vitro human nasal epithelial cells viability after Rhinovirus, Adenovirus, coronavirus OC43 and flu infection.
Healsea® Babykids is a nasal spray indicated in children above 2 years to clean and moisten the nose during colds and rhinitis.
The common cold is an acute viral infection of the upper respiratory tract, involving, to variable degrees, sneezing, nasal congestion and discharge (rhinorrhea), sore throat, cough, low-grade fever, headache, and malaise. Acute viral rhinitis is generally self-limiting. In children where the illness is not self-limiting and extends beyond 7-10 days, many agree that a bacterial infection is likely. Bacterial over infections and progression to a chronic state are favoured by the formation of biofilms, which facilitate bacterial growth and persistence as well as reducing antibiotic efficacy.
The aim of this study is to demonstrate that Healsea® Babykids alleviates symptoms of the acute rhinitis phase with better efficacy than isotonic saline solution used as Placebo.
The study comprises 2 parts:
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
Masking Description
The investigational device and the comparator were indistinguishable. The comparator (isotonic nasal spray) used the same technology and the same packaging than Healsea Babykids. A white label with regulatory mentions for clinical investigations was stuck on the vial A white label with regulatory mentions was sticked on a white cardboard box used as secondary packaging. The IFUs (Bulgarian version) was included in the secondary packaging (on one face, Healsea Babykids, on the other face Placebo
Eligibility Criteria
- Ages
- 25 Months to 6 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male/Female subjects >2 and ≤6-year-old
- •Acute infectious rhinitis/rhinosinusitis for ≤48h before trial entry
- •Patient presenting with fever ≥ 37.5 °C at screening
- •Subjects with nasal congestion (blocked / stuffy nose) rated at least as moderate on the Acute Rhinitis Symptoms Severity Questionnaire, based on evaluation by the investigator
- •Subjects showing at least moderate grade for at least one of the following additional signs of acute rhinitis: runny nose, nasal crust (dry mucus), sneezing and cough
- •Written consent obtained from parent/legal guardians
Exclusion Criteria
- •Known hypersensitivity/allergy to any component of the test device
- •Medical history that is considered by the investigator as a reason for non-inclusion,
- •Severe nasal septum deviation or other condition that could cause nasal obstruction such as the presence of nasal polyps
- •History of nasal or sinus surgery that in the opinion of the investigator may influence symptom scores
- •Antibiotic intake within 2 weeks before screening
- •Systemic corticosteroids within 4 weeks before screening
- •Chronic decongestant use
- •Recent (within the previous 2 days) intake of a common cold medicine that in the opinion of the investigator may influence ARSSQ score at screening (NSAID, nasal decongestants, cough medicines)
Outcomes
Primary Outcomes
The Area Under the Curve (AUC) of the Global Score of the Acute Rhinitis Symptoms Severity Questionnaire (ARSSQ) During First 10 Days of Symptoms - Full Analysis Set (FAS)
Time Frame: From Day 1 to Day 10
ARSSQ is a non-validated customized questionnaire. It includes 10 items assessing symptoms (questions 2 to 7), functional impairments (8 to 10), and global severity (question 1). Each item is scored from 0 (not present/no impact/ not sick) to 3 (severe, severe impact and very sick) for symptoms, functional impairment and global severity respectively. The questionnaire is to be completed in a diary once daily in the evening. The minimum ARSSQ score is zero (0) and the maximum ARSSQ score is thirty (30).
The Area Under the Curve (AUC) of the Global Score of the Acute Rhinitis Symptoms Severity Questionnaire (ARSSQ) During First 10 Days of Symptoms - Per Protocol Set (PP)
Time Frame: From Day 1 to Day 10
ARSSQ is a non-validated customized questionnaire. It includes 10 items assessing symptoms (questions 2 to 7), functional impairments (8 to 10), and global severity (question 1). Each item is scored from 0 (not present/no impact/ not sick) to 3 (severe, severe impact and very sick) for symptoms, functional impairment and global severity respectively. The questionnaire is to be completed in a diary once daily in the evening. The minimum ARSSQ score is zero (0) and the maximum ARSSQ score is thirty (30).
Secondary Outcomes
- Duration of Each Cold Symptom (Questions 2 to 7 of the ARSSQ) in Both Groups(Through study completion, up to Day 18)
- Duration of Quality-of-life Impairment (Questions 8 to 10 of the ARSSQ).(Through study completion, up to Day 18)
- Cumulative Number of Days of Mucolytics Intake(Through study completion , up to day 18)
- Cumulative Number of Days of Concomitant Treatments Use That May Affect Common Cold Symptoms (Antibiotics, Antipyretics, Systemic or Local Mucolytics, Decongestants, Antitussives, Systemic and Topical Corticosteroids)(Through study completion, up to Day 18)
- Cumulative Number of Days of Antibiotics Intake(through study completion , up to day 18)
- Cumulative Number of Days of Antipyretics Intake(through study completion, up to day 18)
- Cumulative Number of Days of Decongestants Use(through study completion, up to day 18)
- Cumulative Number of Days of Antitussives Use(through study completion, up to day 18)
- Cumulative Number of Days of Systemic and Topical Corticosteroids Use(Through study completion, up to day 18)